Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.

Prior treatment

• Post-organ transplant or preparing for organ transplantation;
• Currently using immunosuppressants;
• Alcohol or drug addicts;

Other illness

• Allergy to interferon;
• History of using telbivudine for antiviral treatment;
• Those with autoimmune diseases, psychiatric disorders, poorly controlled diabetes, or thyroid dysfunction (hyperthyroidism or hypothyroidism);
• Confirmed or suspected liver cancer or other malignant tumors;
• HIV co-infection;
• Other conditions deemed unsuitable for interferon use by the attending physician.

Lab values

• ALT(Alanine Aminotransferase) greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal;
• Neutrophil count \< 1.5 x 10\^9/L or platelet count \< 80 x 10\^9/L;

Other

• Decompensated liver cirrhosis;
• Presence of severe lesions in vital organs such as the cardiovascular, pulmonary, renal, brain, and fundus;
• Pregnant or planning to become pregnant within 2 years;

• Age18-65 years (inclusive of 18 and 65), no restriction on gender;
• HBsAg positive history for at least 6 months;
• Family history of liver cancer \[including first-degree and second-degree relatives; first-degree relatives are parents, children, and siblings (same parents), while second-degree relatives are uncles, aunts, grandparents, and great-grandparents; a family history of liver cancer means that one or more first-degree or second-degree relatives have had liver cancer\];
• Planning to or already receiving treatment with Peginterferon alpha-2b in combination with nucleoside (acid) analogs, or receiving nucleoside (acid) analogs treatment alone;
• Negative urine or serum pregnancy test within 24 hours before the first dose (for women of childbearing age);
• Willing to receive treatment and sign an informed consent form.